Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01428076 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)

A Phase 1 study of Varicose Veins, sponsored by Boston Scientific Corporation.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target
1
Study location

NCT01428076 is a Phase 1 study of Varicose Veins that has completed, run by Boston Scientific Corporation. The registered enrollment target is 21 participants, below the 167-participant average among 6 other Varicose Veins trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01428076, a Phase 1 study of Varicose Veins, has completed, sponsored by Boston Scientific Corporation.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the pharmacokinetic profile of two different doses of an investigational drug, Polidocanol Endovenous Microfoam (PEM), an investigational treatment for varicose veins.

Conditions Studied

Interventions

  • DRUG Polidocanol Endovenous Microfoam (PEM)

Study Locations (1)

Florida

  • Cardiovascular and Vein Center of Florida - Bradenton

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2011-08
Est. Completion 2012-01
Phase Phase 1

Sponsor

Boston Scientific Corporation

280 total trials

What the Registry Record Tells You About NCT01428076

The ClinicalTrials.gov registry entry for NCT01428076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 167-participant average among 6 other Varicose Veins trials with a reported enrollment target (87% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Varicose Veins appearing as the primary indexed condition, and to 1 intervention - of which Polidocanol Endovenous Microfoam (PEM) is the first listed.

NCT01428076 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01428076 about?

NCT01428076 is a clinical study titled "Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)". Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and may cause discomfort. In this study, patients with varicose veins in the legs will be participating. The purpose of this research study is to evaluate the pharmacokinetic profile of two different doses of an ...

What is the current status of trial NCT01428076?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-08. Estimated completion is 2012-01.

What conditions does trial NCT01428076 study?

This clinical trial studies the following conditions: Varicose Veins.

What interventions are being tested in trial NCT01428076?

The interventions under investigation include: Polidocanol Endovenous Microfoam (PEM) (DRUG).

Who is sponsoring clinical trial NCT01428076?

This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01428076 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Varicose Veins

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.